Treats acute bacterial skin and skin structure infections (ABSSSI) caused by designated…. Sold as Sivextro. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Tedizolid Phosphate (sold as Sivextro), first approved Jun 20, 2014, with 6 new uses approved and 0 published complete response letters.
| Sivextro | Part D | $32.1M | +94% | 731 |
| Sivextro | Part B | $48K | -6% | 15 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)Tuberculosis, Multidrug Resistant Tuberculosis · Assistance Publique - Hôpitaux de Paris | Phase 2 | Recruiting | Sep 9, 2022 |
| Jun 20, 2014 | SivextroNDA 205435 · New molecular entity | Cubist Pharms LLC | 15 | Marketed |
| Jun 20, 2014 | SivextroNDA 205436 · New dosage form | Cubist Pharms LLC | 11 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA